Artelo biosciences announces publication of new peer-reviewed research demonstrating protective properties of art27.13 against muscle degeneration caused by certain cancers

Solana beach, calif., nov. 09, 2023 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced new research published in the peer-reviewed journal pharmaceuticals. the research article, titled “ cancer-cachexia-induced human skeletal muscle myotube degeneration is prevented via cannabinoid receptor 2 agonism in vitro ,” highlights the promising protective properties of the company's clinical asset, art27.13, in helping prevent muscle degeneration caused by cancer.
ARTL Ratings Summary
ARTL Quant Ranking